STIM Company Profile and Key Details

Neuronetics, Inc. generated EPS of -$0.82 over the past year. Five-year average earnings growth is 2.71%. Wall Street analysts project EPS growth of 37.99% annually over the next five years. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at -$0.11. Next year's EPS is expected at $15.95. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $3.00. The high target offers 66.11% upside. The low target suggests -0.33% downside. The mean target is $4.00. This offers 32.89% upside. Neuronetics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by -59.35%. The prior quarter beat by -5.88%. Over the last six quarters, Apple has recorded several small beats. These include 61.54% in May 06, 2025.

Neuronetics, Inc. (NASDAQ:STIM) closed at $3.01 USD, losing -$0.03 (-0.99%) from the previous close of $3.04. The stock is currently mid-range between its 52-week high and low $0.80 and $3.44. With a market capitalization of about $209.46 million, Neuronetics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 2.16 million shares, volume is running light vs its 52-week average. Headquartered in Malvern, PA, Neuronetics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Daniel L. Reuvers, the company employs approximately 658 people and listed since June 28, 2018. Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S.

Short-term trend indicators are bullishly aligned (SMA20 -8.65%, SMA50 -14.77%, SMA200 -49.04%). The stock’s 14-day RSI is 44.26 (neutral), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.01% below its high and over 18.14% above its low. Average 10-day trading volume of 1.02 million shares is below the 3-month average of 2.09 million, indicating normal recent market interest.

Our AI price prediction model suggests that Neuronetics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.29%, with price expected at $3.38 by September 24, 2026, within a range of $2.93 to $3.78 3-Month Outlook: Projected rise of 97.67%, reaching $5.95 by December 08, 2026, with a range of $5.70 to $6.30. 1-Year Outlook: Projected gain of 718.6%, with price at $24.64 by September 10, 2027, within a range of $15.41 to $36.98.

Neuronetics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $10.27. This means the shares are trading below this model’s fair value.

Neuronetics, Inc. has 76.20 million shares outstanding. The public float is 37.15 million shares, elevated short interest at 27.16% of float. This equals 9.33 million shares. The short ratio is 4.71 days. Institutional investors hold 78.1% of the float. Insiders own 30.85%. Chernett Jorey holds 10.60 million shares, CANNELL CAPITAL LLC has 3.13 million shares and Sullivan Keith J has 1.59 million shares. Over the past six months, insider transactions show net buying. They sold 70.96 thousand shares across 4 transactions.

Neuronetics, Inc. (NASDAQ:STIM) shares are up 40.22% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Neuronetics, Inc. trading at a premium to the broader market with a P/E of -6.98. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.10, suggesting 135.88% upside. Our AI forecast model points to short-term strength (12.29% over two weeks), a medium-term rise (97.67% over three months), and a longer-term gain (718.6% over one year), with expected trading ranges indicating moderate volatility.

Neuronetics, Inc. trades at a P/E ratio of -6.98, slightly below the S&P 500 average, with a price-to-sales ratio of 1.35 and a price-to-book ratio of 12.0 reflecting a rich premium to book value. The P/FCF stands at -20.74, also below market averages. Compared to sector medians, Neuronetics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.